Active ingredients: empagliflozin
What it is used for
Glycaemic control JARDIANCE is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as: - Monotherapy: When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance. - Add-on combination therapy: In combination with other glucoselowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see CLINICAL TRIALS). Prevention of cardiovascular death JARDIANCE is indicated in patients with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see CLINICAL TRIALS). To prevent cardiovascular deaths, JARDIANCE should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care.
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Oral
- Store below 30 degrees Celsius
- Store in Original Container
- Lifetime is 36 Months.
Always read the label. If symptoms persist see your healthcare professional.
Pale yellow, round, biconvex and bevel-edged film-coated tablet, debossed with 'S10' on one side, the other side debossed with the BI company symbol
Images are the copyright of the Pharmacy Guild of Australia
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient empagliflozin
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf)